Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma
| Autor: | Thomas King, Daniel Quirk, Robert Mass, Shamlal Mangray, Todd M. Moore, Howard Safran, Margaret M. Steinhoff, Umadevi Tantravahi, Ritesh Rathore, Terese Pasquariello, Katya Berzein, David A. Iannitti, Paul A. Akerman, Philip T. Reiss, Li Chai, Lisa Goldstein |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Male
Cancer Research Pathology medicine.medical_specialty Pancreatic disease Receptor ErbB-2 Antineoplastic Agents Antibodies Monoclonal Humanized Trastuzumab Pancreatic cancer medicine Carcinoma Humans In Situ Hybridization Fluorescence Aged medicine.diagnostic_test business.industry Antibodies Monoclonal Middle Aged medicine.disease Immunohistochemistry Pancreatic Neoplasms medicine.anatomical_structure Oncology Cancer research Adenocarcinoma Female Pancreas business medicine.drug Fluorescence in situ hybridization Carcinoma Pancreatic Ductal |
| Zdroj: | American journal of clinical oncology. 24(5) |
| ISSN: | 0277-3732 |
| Popis: | Novel systemic treatments are needed in pancreatic cancer. The authors sought to establish the frequency of overexpression of the HER-2/neu oncogene in patients with pancreatic adenocarcinoma to determine the potential role of trastuzumab (Herceptin) as a therapeutic agent in this disease. Tumor specimens from patients with pancreatic adenocarcinoma were analyzed by staining for p185HER2 protein using the DAKO immunohistochemical assay. Patients with and without HER-2/neu overexpression by immunohistochemistry were compared with respect to clinical and pathologic characteristics. HER-2/neu gene amplification was also evaluated by fluorescence in situ hybridization (FISH). Thirty-two of 154 patients (21%) had pancreatic adenocarcinoma that demonstrated HER-2/neu overexpression by immunohistochemistry. At initial diagnosis, 16% of resectable cancers, 17% of locally advanced cancers, and 26% of metastatic cancers were determined to have HER-2/neu overexpression. Three of 11 (27%) patients with HER-2/neu overexpression by immunohistochemistry had gene amplification by FISH. HER-2/neu overexpression occurs in a subset of pancreatic cancer. Evaluation of the efficacy of trastuzumab for patients with pancreatic cancer who overexpress HER-2/neu appears indicated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|